Antiemetic Agent

2020 ◽  
Author(s):  
Keyword(s):  
Antiemetic Agent

scholarly journals Ondansetron use is associated with lower COVID-19 mortality in a Real-World Data network-based analysis

2021 ◽  
Author(s):  
Gregory M Miller ◽  
Austin J Ellis ◽  
Rangaprasad Sarangarajan ◽  
Amay Parikh ◽  
Leonardo O Rodrigues ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Real World ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Long Term Effects ◽  
Real World Data ◽  
World Data ◽  
Antiemetic Agent ◽  
Future Loss ◽  
Selection Operator

Objective: The COVID-19 pandemic generated a massive amount of clinical data, which potentially holds yet undiscovered answers related to COVID-19 morbidity, mortality, long term effects, and therapeutic solutions. The objective of this study was to generate insights on COVID-19 mortality-associated factors and identify potential new therapeutic options for COVID-19 patients by employing artificial intelligence analytics on real-world data. Materials and Methods: A Bayesian statistics-based artificial intelligence data analytics tool (bAIcis®) within Interrogative Biology® platform was used for network learning, inference causality and hypothesis generation to analyze 16,277 PCR positive patients from a database of 279,281 inpatients and outpatients tested for SARS-CoV-2 infection by antigen, antibody, or PCR methods during the first pandemic year in Central Florida. This approach generated causal networks that enabled unbiased identification of significant predictors of mortality for specific COVID-19 patient populations. These findings were validated by logistic regression, regression by least absolute shrinkage and selection operator, and bootstrapping. Results: We found that in the SARS-CoV-2 PCR positive patient cohort, early use of the antiemetic agent ondansetron was associated with increased survival in mechanically ventilated patients. Conclusions: The results demonstrate how real world COVID-19 focused data analysis using artificial intelligence can generate valid insights that could possibly support clinical decision-making and minimize the future loss of lives and resources.

scholarly journals Effects of N-3389, a novel antiemetic agent, on colonic function in animals

1997 ◽  
Vol 73 ◽  
pp. 222
Author(s):  
Sugure Taniguchi ◽  
Koichiro Hagihara ◽  
Takeo Arai ◽  
Toru Hayakawa ◽  
Setsuko Mino ◽  
...  
Keyword(s):  
Antiemetic Agent

scholarly journals Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies

2020 ◽  
Author(s):  
Rudolph M Navari ◽  
Eric J Roeland
Keyword(s):  
Cancer Care ◽  
Rescue Medication ◽  
Cost Effective ◽  
Complete Response ◽  
Nausea And Vomiting ◽  
Antiemetic Agent ◽  
Chemotherapy Administration ◽  
Antiemetic Guidelines ◽  
Intravenous Hydration ◽  
Antiemetic Agents

Breakthrough chemotherapy-induced nausea and vomiting (CINV) is nausea and/or vomiting occurring within 5 days of chemotherapy administration despite using guideline-directed prophylactic antiemetic agents. It is highly prevalent (30–40%), usually requiring immediate treatment or “rescue” medication. If breakthrough CINV occurs, antiemetic guidelines recommend using an antiemetic agent from a different class not used in prophylaxis, along with intravenous hydration and/or dexamethasone. Data supporting these guideline recommendations are limited. Importantly, costs associated with breakthrough CINV can be substantial (i.e., unscheduled hydrations). Two retrospective analyses evaluating guideline-adherent CINV prophylaxis suggest that the initial antiemetic selection may decrease breakthrough CINV. Here we review optimal CINV prophylactic strategies and introduce unscheduled hydration as a potential important surrogate for breakthrough CINV aligning with cost-effective cancer care.

scholarly journals Safety of Metoclopramide in Traumatic Brain Injury (TBI) Patients

2020 ◽  
Author(s):  
Said Al Jaadi ◽  
Yahya Al-Kindi ◽  
Tariq Al-Saadi
Keyword(s):  
Side Effect ◽  
Brain Injuries ◽  
Traumatic Brain Injuries ◽  
Review Of The Literature ◽  
Inclusion Criteria ◽  
Antiemetic Agent ◽  
Presenting Symptoms ◽  
The Central Nervous System ◽  
Multiple Variables ◽  
Cns Side Effects

Abstract Introduction Traumatic brain injuries (TBIs) occur due to severe head assault to a hard object, with headache and vomiting being amongst the most common presenting symptoms. Metoclopramide is an old antiemetic agent that has been used widely for nausea and vomiting in TBI patients. Aim A systematic review of the literature to investigate the safety of metoclopramide in treating TBI patients. Methods A literature review was conducted in six databases, where we determined the pertinence of a study to the inclusion criteria by assessing the title, keywords, and abstracts. Five studies were found to be relevant. Data were extracted using multiple variables that were formulated incongruent with the study aim and then further analyzed. Results The collective sample size was 93 patients with an average of age 38.5 years. As much as 51.6% were male and 48.6% were females. Most patients received 10 mg metoclopramide IV with a percentage of 77.4%, while only 22.5% received 20 mg IV metoclopramide. Seventy-one patients received metoclopramide alone and 22 received combination therapy. Headache was the most common reported side effect (46.2%), followed by anxiety and drowsiness with (39.7%) and (27.9%), respectively. Fatigue was reported in 24.7%, while dystonia was the least common and developed in only 5.3% of patients. Conclusion Metoclopramide is a common medication used to treat TBI patients in the emergency department. However, the review demonstrated that the central nervous system (CNS) side effect is excepted. Treatments with lower CNS side effects may be better options.

Synthesis of several 4-hydroxy-3,5-dimethoxybenzamides, their O-substituted derivatives and some related compounds as potential neurotropic agents

1985 ◽  
Vol 50 (2) ◽  
pp. 510-518 ◽  
Author(s):  
Vladimír Valenta ◽  
Miroslav Protiva
Keyword(s):  
Blood Pressure ◽  
Catalytic Hydrogenation ◽  
Anticonvulsant Activity ◽  
Sodium Hydride ◽  
Antiemetic Agent ◽  
Related Compounds ◽  
Neurotropic Agents ◽  
Amino Ether

Reactions of 4-benzyloxy-3,5-dimethoxybenzoyl chloride with pyrrolidine, piperidine, morpholine and 1-methylpiperazine gave the amides IIIa-IIId which were debenzylated by catalytic hydrogenation on palladium. The 4-hydroxy-3,5-dimethoxybenzamides IVa-IVc were then treated with sodium hydride and 2-dimethylaminoethyl chloride to give the O-(2-dimethylaminoethyl)amides Va-Vc. The 3,4,5-trimethoxybenzamide IX was prepared as a homologue of the antiemetic agent "trimethobenzamide" (II) and reduced to the benzylaniline derivative X. The substituted nicotinamide XI was obtained from nicotinoyl chloride and 4-(2-diethylaminoethoxy)aniline. Out of the compounds prepared the amides IIId and Vc had some anticonvulsant activity, the piperazide IVd revealed a significant α-adrenolytic effect and the amino ether X reduced the blood pressure of normotensive rats.

Clinical evaluation of fluphenazine dihydrochloride*as antiemetic agent

1962 ◽  
Vol 41 (6) ◽  
pp. 732???739 ◽  
Author(s):  
JOHN J. BONICA ◽  
HENRY D. GREEN ◽  
H. LORING DIXON ◽  
DAVID N. GOODSON ◽  
MARGARET RENSAA ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Antiemetic Agent
Sign in / Sign up

Export Citation Format

Share Document